Phathom Pharmaceuticals Announces Additional Phase 3 Trial Results for VOQUEZNA

On October 25, 2025, Phathom Pharmaceuticals, Inc. announced the publication of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease (NERD) in the American Journal of Gastroenterology. The study highlights the significant burden of nighttime GERD symptoms and the potential role of VOQUEZNA in addressing this aspect of the disease. The trial involved 772 patients randomized to VOQUEZNA 10 mg, 20 mg, or placebo for an initial 4-week period, followed by a 20-week extension. Key findings include a higher percentage of heartburn-free nights for VOQUEZNA compared to placebo, rapid onset of effect, sustained improvements in patient-reported outcomes, and durability of symptom relief throughout the treatment period. VOQUEZNA was generally well tolerated, with common adverse events including nausea, abdominal pain, and urinary tract infection. The report also includes forward-looking statements regarding the potential clinical profile of VOQUEZNA and Phathom’s business strategy.